
Prolight Diagnostics develops POC systems that deliver test results in 10 minutes or less.
prolightdx.comCrawled Nov 17, 2026
Prolight Diagnostics receives ‘Intention to Grant’ notifications from the European Patent Office for two patent applications covering its Psyros single-molecule-counting technology. The patents, officially notified on **28 October 2026**, expand the company’s intellectual property portfolio for its diagnostic platform.
Prolight Diagnostics secures its first order worth approximately **SEK 19.9 million** from **BRAINBox**, a company specializing in traumatic brain injury (TBI) solutions. The deal covers commercial products ahead of BRAINBox’s upcoming **U.S. launch**. The order marks Prolight’s entry into the TBI diagnostic market with a high-value contract.
Prolight Diagnostics secures a **USD 3.9 million** first-year supply agreement with **BRAINBox Solutions** for its **Psyros® point-of-care platform**, supporting commercialization of BRAINBox’s traumatic brain injury diagnostic and prognostic tools. The deal covers instruments and cartridges, pending FDA clearance and market launch. Prolight specializes in digital point-of-care testing solutions.
Prolight Diagnostics secures a **GBP 2.24 million** development agreement with **BRAINBox Solutions** following a 260-patient feasibility study. The deal covers evaluation of BRAINBox’s FDA Pivotal Study samples on Prolight’s **Psyros point-of-care platform**. Most revenues (**GBP 2.09 million**) are recognized in the second half of 2026.
Prolight Diagnostics secures a **Notice of Allowance** from the USPTO for its **Psyros®** single-molecule-counting technology patent. The patent (US application No. 18/267,726) covers methods to prolong the lifespan of reactive oxygen species, improving spot clarity in its diagnostic platform. This marks the company’s first granted U.S. patent for the Psyros system.
Prolight Diagnostics finalizes the design specifications for its Psyros platform instrument, marking a critical step toward advancing into clinical development and enabling scalable production.
Prolight Diagnostics receives a second patent in Japan for its **Psyros single-molecule-counting technology**, granted by the Japan Patent Office (JPO). The patent reinforces the company’s intellectual property portfolio in a key market. The official Decision to Grant was issued on **April 24, 2026**, marking a milestone for the company’s proprietary diagnostic platform.
Prolight Diagnostics secures a semi-finalist spot in the **ADLM 2026 Disruptive Technology Award Competition**, recognizing its advancements in point-of-care diagnostic technology. The selection grants the company guaranteed exhibition space in the **Disruptive Technology area** at the **ADLM annual meeting** in Anaheim, California, from **July 26–30, 2026**. The award highlights Prolight’s innovation in medical diagnostics within the industry.